Paramjeet Kaur from CDER’s Office of Generic Drugs discusses the role of Abbreviated New Drug Application (ANDA) assessors in Product-Specific Guidance (PSG) development, the impact of recommendations in PSGs on ANDA assessments with case studies, and alternate bioequivalence (BE) approach proposal(s) to PSG recommendations with case studies.
Learn more at [ Ссылка ]
_______________________________
FDA CDER’s Small Business and Industry Assistance (SBIA) educates and provides assistance in understanding the regulatory aspects of human drug products & clinical research.
Upcoming Training - [ Ссылка ]
SBIA Listserv - [ Ссылка ]
SBIA 2021 Playlist - [ Ссылка ]
SBIA LinkedIn: [ Ссылка ]
SBIA Training Resources - [ Ссылка ]
Twitter - [ Ссылка ]
Email - CDERSBIA@fda.hhs.gov
Phone - (301) 796-6707 I (866) 405-5367
